CONTEXT: A study title that may slip through unnoticed as it does not explicitly mention RWR, but an interesting study showing how RWE can inform physicians on the impact of treatment and disease on oncology patients as they approach end-stage | Includes a podcast of the study, which is a nice touch.
IMPACT: Medium
READ TIME: 2 mins
Quality Level Mean [1 – 10]: 6
1. “Xin Shelley Wang, MD, MPH, The University of Texas MD Anderson Cancer Center, Houston, discusses results from a real-world study exploring patient-reported outcomes (PROs) of symptom burden and functioning among patients with advanced esophageal, gastroesophageal junction, and gastric cancer undergoing chemotherapy.”
2. “We appreciate this opportunity to present our study titled “Patient‑Reported Symptom Burden and Functioning in Patients with Advanced Gastroesophageal Junction and Gastric Cancer Undergoing Chemotherapy.””
3. “If a high symptom burden initial the time of the therapy, usually patient continues to remain in the high symptom burden over time.”
4. “Conclusion for this observational study from the real‑world data, we observed that a patient with very advanced stage of upper GI cancer undergoing standard therapy, more than half of them suffer from a high symptom burden, persistently.”
5. “It’s really supportive for a well‑targeted cluster of symptoms to be monitored over time during the therapy and to provide patient persist symptom management and also identify the patients in the high‑risk development of high symptom burden.”